Congenital Dyserythropoietic Anemia Type I

Congenital dyserythropoietic anemia, type I, usually called CDA type I, is a rare inherited blood disease. In this disease, the bone marrow tries to make red blood cells, but many of those young red blood cells do not grow in the normal way. Because of that, the body cannot make enough healthy red blood cells, and the person develops anemia. Red blood cells carry oxygen, so when they are low or abnormal, the body can feel weak, tired, and pale. CDA type I is usually linked to changes in the CDAN1 gene or the CDIN1 gene, and it is most often passed down in an autosomal recessive way, which means a child usually gets one changed gene copy from each parent.

Congenital dyserythropoietic anemia type I, usually called CDA type I, is a very rare inherited blood disorder. In this disease, the bone marrow makes red blood cells in an abnormal way, so many cells die before they fully mature. This causes chronic anemia, jaundice, tiredness, enlarged spleen, and over time iron overload, even in some people who do not get many transfusions. CDA type I is most often linked to changes in CDAN1 or C15orf41/CDIN1 genes. In severe cases it can start before birth; in milder cases it may be found later in childhood or adulthood. [1][2][3]

This disease can start before birth, in infancy, in childhood, or later, but many people are diagnosed in childhood or adolescence. Some babies may have jaundice, enlarged liver, or poor growth before or soon after birth. Many older children and adults have long-term anemia, jaundice, and splenomegaly, which means an enlarged spleen. Some people also develop iron overload, even if they do not receive many blood transfusions, and this extra iron can slowly harm the liver, heart, and other organs.

Other names

Other names for this condition include CDA I, CDA type 1, CDA1, and dyserythropoietic anemia, congenital type 1. These names all point to the same rare inherited disorder. Doctors may use slightly different wording in medical reports, but they mean the same disease group.

Types

1. CDAN1-related CDA type I means CDA type I caused by disease-causing changes in the CDAN1 gene. This is a well-known cause of the disease. The gene helps normal red blood cell development, so when it does not work well, red blood cell production becomes abnormal.
2. CDIN1-related CDA type I means CDA type I caused by disease-causing changes in the CDIN1 gene, which was previously called C15orf41 in older literature. This form also causes abnormal red blood cell development and anemia.

Causes

CDA type I is a genetic disease, so its real causes are mainly gene changes and inheritance patterns, not food, infection, or lifestyle. To make this easy to understand, the list below includes the main direct causes and the main genetic situations that lead to the disease.

1. Disease-causing change in the CDAN1 gene is one main cause of CDA type I. When this gene is altered, red blood cell formation becomes faulty.
2. Disease-causing change in the CDIN1 gene is another known cause. This gene is also important for proper red blood cell development.
3. Having two altered copies of CDAN1 can cause the disease. One changed copy usually comes from the mother and one from the father.
4. Having two altered copies of CDIN1 can also cause the disease in the same recessive pattern.
5. Autosomal recessive inheritance is the usual genetic reason this disease appears in a child. A person often becomes affected only when both gene copies are abnormal.
6. Being born to two carrier parents raises the chance that a child will inherit two changed copies and develop CDA type I.
7. Family history of CDA type I increases the chance that the disease is present in relatives because this disorder runs in families.
8. Consanguinity, or parents being biologically related, can increase the chance of recessive diseases like CDA type I because the same rare gene change may come from both sides of the family. This is a general genetic risk pattern for recessive disorders.
9. Faulty late red blood cell development is a disease mechanism behind CDA type I. The marrow makes erythroblasts, but many of them do not mature normally.
10. Ineffective erythropoiesis is another core cause of the anemia. This means the marrow tries to make red blood cells, but too many cells fail before becoming useful mature cells.
11. Abnormal erythroblast morphology causes poor red blood cell production. Under the microscope, the young cells look unusual, showing that the marrow process is not normal.
12. Defective maturation of immature red blood cells directly leads to fewer healthy circulating red cells and therefore anemia.
13. Abnormal chromatin structure in erythroblasts is a characteristic disease mechanism in CDA type I. This abnormal nuclear pattern is part of why the cells cannot develop well.
14. Spongy heterochromatin on electron microscopy is a classic cell abnormality in CDA type I and reflects the underlying gene-related problem in red cell precursors.
15. Reduced production of functional mature red blood cells is a direct biological cause of the chronic anemia seen in this disease.
16. A hemolytic component, meaning some red cells break down more than normal, can add to the anemia in CDA type I.
17. Increased body iron absorption is part of the disease process in many patients. This does not usually start the disease, but it is caused by the disease biology and becomes a major complication.
18. Unknown genetic cause in a minority of cases may explain some people with CDA type I features when CDAN1 and CDIN1 testing is negative. MedlinePlus notes that a small percentage of cases still have an unknown cause.
19. Before-birth severe anemia from the same inherited disorder can happen in some affected babies. In these cases, the same gene problem causes fetal anemia and sometimes hydrops fetalis.
20. Inherited defects affecting erythropoiesis from birth summarize the broad cause of CDA type I. It is not an acquired disease; it is an inborn disorder of red blood cell production.

Symptoms

1. Tiredness is very common because the body has fewer healthy red blood cells to carry oxygen. When oxygen delivery falls, the body feels low in energy.
2. Weakness happens for the same reason. Muscles and organs do not get the oxygen they need, so everyday activity may feel harder.
3. Pale skin can happen because anemia reduces the normal red color carried by blood. This may be seen in the face, lips, or inner eyelids.
4. Jaundice, which means yellow color of the skin or eyes, is common. It happens when bilirubin rises as red blood cells are broken down.
5. Enlarged spleen is a frequent symptom and sign. The spleen may grow because it is working harder to remove abnormal blood cells.
6. Enlarged liver can occur, especially in babies or in people with iron overload. The liver may also store extra iron over time.
7. Shortness of breath on activity can happen when anemia is more severe, because the body tries to get more oxygen.
8. Fast heartbeat or feeling the heart beat strongly may happen as the body tries to move more oxygen around. This is a common effect of anemia in general and may appear in CDA type I when anemia is important.
9. Poor growth before birth may be seen in some affected babies. This can show up as intrauterine growth restriction.
10. Early jaundice in newborns can be one of the first clues in infancy. A baby may look yellow soon after birth.
11. Gallstones may develop in some patients because long-term red blood cell breakdown can increase pigment load in bile.
12. Short stature may occur in some people with CDA type I. This means the child may be shorter than expected for age.
13. Finger or toe abnormalities can be present in some patients. These are not seen in everyone, but they are recognized features of CDA type I.
14. Iron overload symptoms may appear later, such as tiredness, liver problems, or heart problems, because extra iron can collect in organs over time.
15. Hydrops fetalis, which means severe swelling of the fetus before birth, is rare but can happen in very severe cases detected during pregnancy.

Diagnostic tests

The diagnosis of CDA type I is usually made by putting together the history, physical exam, blood tests, bone marrow findings, and genetic testing. Some tests confirm the disease itself, while others check complications like iron overload, gallstones, or organ damage.

Physical exam tests

1. General physical examination is the first step. The doctor looks at overall health, skin color, energy level, growth, and signs of chronic anemia.
2. Inspection for pallor means the doctor checks for unusual paleness in the skin, lips, nail beds, and inner eyelids. This can suggest anemia.
3. Inspection for jaundice means looking for yellow color in the eyes or skin. This gives a clue that red blood cells may be breaking down faster than normal.
4. Growth and height assessment is important, especially in children, because some patients with CDA type I have short stature or poor growth.

Manual tests

5. Palpation of the spleen means the doctor gently feels the abdomen to check whether the spleen is enlarged. Splenomegaly is common in CDA type I.
6. Palpation of the liver means gently feeling the right upper abdomen to see if the liver is enlarged. Hepatomegaly can be present in newborns and in people with iron overload.
7. Abdominal percussion and organ size assessment help the doctor estimate liver and spleen size more carefully during the bedside exam. This does not confirm the disease alone, but it supports the diagnosis.
8. Examination of fingers, toes, and limbs is done by looking and gently moving the hands and feet, because some people with CDA type I have skeletal or distal limb abnormalities.

Lab and pathological tests

9. Complete blood count, or CBC, measures hemoglobin, red blood cell number, and red blood cell size. CDA type I often shows anemia and can be macrocytic, meaning the red cells are larger than usual.
10. Reticulocyte count checks how many young red blood cells are entering the blood. In CDA, the response may be lower than expected for the degree of anemia because erythropoiesis is ineffective.
11. Peripheral blood smear looks at blood cells under a microscope. It can show abnormal red cell shapes and gives clues that this is not a simple iron deficiency anemia.
12. Bilirubin blood test measures bilirubin, which often rises when red blood cells break down more than normal. This supports jaundice and a hemolytic component.
13. Lactate dehydrogenase, or LDH, may be checked because it can rise when there is increased red blood cell breakdown or marrow cell destruction. It helps assess hemolysis.
14. Haptoglobin test may help check whether hemolysis is contributing to the anemia. Low haptoglobin can support increased red cell destruction.
15. Iron studies, including serum ferritin and often transferrin saturation, are very important because CDA type I can cause iron overload even without many transfusions.
16. Liver function tests may be ordered to see whether iron overload or chronic hemolysis is affecting the liver. These tests do not confirm CDA type I by themselves, but they help assess complications.
17. Bone marrow aspiration and biopsy are classic diagnostic tests. The marrow is examined to look for abnormal erythroblasts and the typical dyserythropoietic pattern.
18. Electron microscopy of bone marrow can show the classic spongy heterochromatin pattern in erythroblasts, which strongly supports CDA type I.
19. Genetic testing is now one of the most important confirmatory tests. A gene panel, exome test, or targeted test can identify disease-causing changes in CDAN1 or CDIN1 and may avoid a long delay in diagnosis.

Electrodiagnostic tests

20. Electrodiagnostic tests are not routine tests for diagnosing CDA type I itself. In simple words, doctors usually do not use nerve tests or muscle electricity tests to confirm this disease, because CDA type I is mainly a blood and bone marrow disorder. If heart iron overload becomes a concern, doctors usually prefer imaging such as MRI and heart assessment rather than classic nerve or muscle electrodiagnostic studies.

Imaging tests

21. Abdominal ultrasound is useful to check the size of the liver and spleen and to look for gallstones. It helps measure complications that are common in long-term disease.
22. Liver MRI with iron measurement, such as T2*, is used to measure iron overload in the liver more accurately. This is important because too much iron can slowly damage the liver.
23. Cardiac MRI with T2* may be used in some patients to check whether extra iron is collecting in the heart. This matters in people with significant iron overload or a long disease course.
24. Skeletal imaging, such as X-ray when needed, may be used if the patient has finger, toe, or other bone abnormalities. This is not needed for every patient, but it can help document associated skeletal changes.

CDA type I is a rare inherited anemia caused mainly by harmful changes in CDAN1 or CDIN1. The bone marrow makes red blood cells in an abnormal way, so many cells do not mature properly. This leads to chronic anemia, jaundice, enlarged spleen, and sometimes enlarged liver, gallstones, bone changes, and iron overload. The most important tests are CBC, blood film, iron studies, bone marrow study, and especially genetic testing.

Non-Pharmacological Treatments

1. Regular hematology follow-up means planned visits with a blood specialist to track hemoglobin, jaundice, spleen size, growth, and complications. Its purpose is early detection of worsening anemia, iron overload, and organ damage. The mechanism is simple: when doctors watch trends over time, they can act before serious harm develops. [5]
2. Routine blood testing includes complete blood count, reticulocyte count, bilirubin, ferritin, and liver tests. Its purpose is to measure anemia severity and iron burden. The mechanism is monitoring the body’s response and spotting silent damage early. [6]
3. Genetic counseling helps families understand inheritance, future pregnancy risk, and testing options. Its purpose is informed family planning. The mechanism is education about autosomal recessive inheritance and family screening when needed. [7]
4. Transfusion planning without overuse is a supportive care strategy. Some people need only occasional transfusions, while severe cases may need more frequent support. The purpose is symptom control and safe oxygen delivery. The mechanism is careful matching of red cell support to real need, while limiting extra iron exposure. [8]
5. Iron overload surveillance uses ferritin testing and liver iron assessment. Its purpose is to prevent heart, liver, and endocrine injury. The mechanism is finding excess iron early, even in some patients who are not heavily transfused. [9]
6. MRI-based liver iron measurement is a noninvasive way to estimate iron in the liver. Its purpose is better chelation decisions. The mechanism is imaging the effect of stored iron in tissue. [10]
7. Growth and development monitoring in children checks height, weight, puberty, and school function. Its purpose is to catch chronic anemia effects early. The mechanism is repeated review of how long-term low hemoglobin affects the whole body. [11]
8. Nutrition support with enough calories and protein helps the body handle chronic disease. Its purpose is to support growth, tissue repair, and energy. The mechanism is giving the marrow and body enough building blocks, even though food alone does not cure CDA I. [12]
9. Folate-rich diet support is often advised because red blood cell production uses folate. Its purpose is to avoid an extra nutritional burden on marrow function. The mechanism is supporting DNA synthesis in rapidly dividing blood-forming cells. [13]
10. Gallbladder monitoring looks for pigment gallstones, which can happen because of chronic hemolysis. Its purpose is early treatment of pain, infection, or blockage. The mechanism is ultrasound follow-up and symptom review. [14]
11. Spleen monitoring checks for splenomegaly and possible hypersplenism. Its purpose is to detect when the spleen worsens anemia or lowers blood counts. The mechanism is exam and imaging to guide later decisions. [15]
12. Bone health assessment is helpful in chronic anemia and iron overload. Its purpose is to protect growth and skeletal health. The mechanism is checking for deformity, pain, vitamin D problems, and reduced bone strength. [16]
13. Liver monitoring includes enzymes, imaging, and iron assessment. Its purpose is to prevent fibrosis and iron-related injury. The mechanism is tracking the organ that stores much of the extra iron. [17]
14. Heart monitoring in heavy iron burden may include exam, ECG, and specialist review. Its purpose is to prevent silent iron-related heart disease. The mechanism is early recognition of rhythm or pumping problems. [18]
15. Endocrine monitoring checks puberty, thyroid, glucose, and hormones in people with significant iron overload. Its purpose is to prevent long-term hormonal injury. The mechanism is finding iron damage before it becomes severe. [19]
16. Vaccination review is important, especially if splenectomy is planned or performed. Its purpose is infection prevention. The mechanism is strengthening immune protection against dangerous bacteria. [20]
17. Pregnancy planning with specialists is important for affected women. Its purpose is to reduce maternal and fetal risk. The mechanism is close monitoring of anemia, iron, transfusion need, and fetal growth. [21]
18. Psychological support and counseling help patients cope with fatigue, hospital visits, and lifelong disease. Its purpose is better quality of life. The mechanism is stress reduction, education, and better treatment adherence. [22]
19. Transplant evaluation in severe cases is a non-drug treatment pathway. Its purpose is to see whether curative stem cell transplant is appropriate. The mechanism is replacing the defective blood-forming system with healthy donor cells. [23]
20. Multidisciplinary care means hematology, genetics, liver care, nutrition, and surgery teams work together. Its purpose is safer, more complete care. The mechanism is treating the whole disease burden, not only the hemoglobin number. [24]

Drug Treatments

The most important drug for CDA type I itself is interferon alfa, while many other medicines are used for complications such as iron overload, pain, infection risk, or nutrient support. [25]

1. Interferon alfa-2a can improve hemoglobin in many CDA I patients. It is an immune-modulating biologic. It is usually given by subcutaneous injection several times a week in published practice. Purpose: raise hemoglobin and reduce transfusion need. Mechanism: it appears to improve ineffective erythropoiesis in CDA I. Side effects can include flu-like symptoms, mood changes, liver effects, and blood count effects. [26]
2. Interferon alfa-2b is another interferon used in CDA I. GeneReviews notes intramuscular or subcutaneous use two or three times weekly. Purpose: improve anemia and lower iron loading over time. Mechanism: modifies marrow red cell production. FDA interferon labels also warn about neuropsychiatric, eye, endocrine, and hepatic risks. [27]
3. Peginterferon alfa-2b may be used once weekly in selected patients. Purpose: similar benefit with less frequent dosing. Mechanism: pegylation makes the drug last longer in the body. FDA labeling warns about serious mental health, liver, and eye risks. [28]
4. Deferasirox is an oral iron chelator used when iron overload develops. It is FDA-approved for chronic transfusional iron overload. Purpose: lower excess body iron. Mechanism: binds iron so it can be removed. Labeling warns about kidney failure, liver failure, and gastrointestinal bleeding. [29]
5. Deferoxamine is an injectable iron chelator. Purpose: remove excess iron when overload is important or oral therapy is unsuitable. Mechanism: binds free iron for excretion. FDA labeling lists hypersensitivity risk and important toxicity monitoring needs. [30]
6. Deferiprone is another iron chelator, sometimes used when current chelation is inadequate. Purpose: lower iron stores. Mechanism: binds iron and increases iron excretion. FDA labeling carries a boxed warning for agranulocytosis and neutropenia. [31]
7. Folic acid is often used as supportive therapy in chronic hemolytic or high-turnover states. Purpose: support red cell production. Mechanism: helps DNA synthesis in marrow cells. It does not correct the genetic defect, but it may help avoid added folate deficiency. [32]
8. Vitamin D may be used when deficiency or bone weakness is present. Purpose: support bone health. Mechanism: improves calcium handling and bone mineralization. [33]
9. Calcium supplementation may be added in selected patients with low intake or bone issues. Purpose: preserve bone strength. Mechanism: supplies needed mineral for bone tissue. [34]
10. Antibiotics are not routine for CDA I itself, but they are used when infections occur or after procedures such as splenectomy. Purpose: prevent or treat bacterial infection. Mechanism: kill or suppress bacteria during vulnerable periods. [35]
11. Pain medicines may be used for gallstone pain, postoperative pain, or procedure-related discomfort. Purpose: symptom relief. Mechanism: reduce pain signaling. [36]
12. Ursodeoxycholic acid may sometimes be used in biliary disease, though it is not a core CDA I drug. Purpose: support bile flow in selected gallbladder or bile duct problems. Mechanism: changes bile composition. [37]
13. Hormone replacement drugs may be needed when severe iron overload damages endocrine glands. Purpose: treat resulting hormone deficiency. Mechanism: replace missing thyroid, sex, or other hormones. [38]
14. Insulin or diabetes medicines may be required if iron overload affects the pancreas. Purpose: control blood sugar. Mechanism: improve glucose handling. [39]
15. Cardiac medicines may be needed if iron overload leads to heart dysfunction. Purpose: protect heart rhythm or pumping. Mechanism: standard heart failure or rhythm control treatment. [40]
16. Laxatives or stool softeners can be useful during iron chelation or after surgery when constipation becomes a problem. Purpose: bowel comfort. Mechanism: improve stool movement. [41]
17. Antiemetics may be used if interferon or chelation causes nausea. Purpose: improve treatment tolerance. Mechanism: reduce nausea pathways. [42]
18. Topical anesthetic or local supportive medicines may be used around injection therapy in patients receiving interferon. Purpose: improve comfort and adherence. Mechanism: reduce local pain or irritation. [43]
19. Transfusion premedications are sometimes used in people with prior transfusion reactions. Purpose: make transfusion safer. Mechanism: reduce allergic or febrile reaction risk. [44]
20. Chelation adjustment medicines and supportive monitoring plans are part of safe treatment, because chelators can injure kidneys, liver, gut, eyes, or hearing if not watched carefully. The purpose is safe long-term iron removal. [45]

Dietary Molecular Supplements

Useful supplements are supportive only. They do not cure CDA I. [46]

Folic acid, vitamin B12, vitamin D, calcium, zinc, vitamin C in cautious amounts, magnesium, protein supplements, omega-3 fatty acids, and multivitamins without iron may be considered based on real deficiency, diet quality, age, and iron status. Their purpose is to support blood production, bone health, growth, and general nutrition. Their mechanism is correction of low nutrient states, not repair of the gene defect. In people with iron overload, supplements that contain iron should usually be avoided unless a clinician proves iron deficiency, which is uncommon in this disease context. [47]

Drugs for Immunity Booster, Regenerative, or Stem Cell Context

There are no established “immunity booster” drugs that treat CDA I directly. The closest evidence-based items in this category are interferon alfa-2a, interferon alfa-2b, peginterferon alfa-2b, and the transplant-related medicines used around hematopoietic stem cell transplantation, such as conditioning and immune-suppression drugs chosen by transplant teams. These medicines are not routine wellness boosters. They are serious therapies used only in special clinical settings. Stem cell transplant remains the only curative option reported for severe, transfusion-dependent CDA. [48]

Surgeries or Procedures

Blood transfusion is a procedure rather than surgery, but it is one of the most important interventions when anemia becomes severe. Cholecystectomy may be done for symptomatic gallstones. Splenectomy is not a standard treatment for CDA I and is usually much less helpful than in some other blood disorders, so it is considered cautiously and only in selected cases. Central venous access placement may be needed in people who require repeated transfusions or intensive treatment. Allogeneic hematopoietic stem cell transplant is the major definitive procedure for severe transfusion-dependent disease because it can replace the defective marrow with donor stem cells. [49]

Preventions

Avoid unnecessary iron tablets. Keep regular blood and iron testing. Do not miss specialist visits. Treat gallstone symptoms early. Maintain good nutrition. Stay current with vaccines. Plan pregnancy with specialists. Follow chelation safety monitoring carefully. Seek early treatment for infection after splenectomy or major procedures. Consider family genetic counseling before future pregnancies. These steps do not prevent the gene disorder itself, but they help prevent many complications. [50]

When to See Doctors

See a doctor urgently for severe tiredness, shortness of breath, fainting, chest pain, very pale skin, deep jaundice, fever, dark urine, severe belly pain, left upper abdominal fullness, or signs of gallstones such as right upper belly pain after food. Also seek care if a person with known iron overload develops swelling, irregular heartbeat, major weakness, growth problems, delayed puberty, or worsening liver tests. These can signal anemia crisis, infection, gallbladder disease, or iron injury to organs. [51]

What to Eat and What to Avoid

Eat a balanced diet with folate-rich foods such as leafy greens, beans, and citrus; enough protein from fish, eggs, dairy, beans, or lean meat; foods with calcium and vitamin D for bone health; and plenty of water. Avoid extra iron supplements unless a doctor confirms iron deficiency. Be careful with high-dose vitamin C supplements because they can increase iron absorption in some settings. Limit alcohol if iron overload or liver stress is present. Avoid extreme dieting because chronic anemia already strains the body. [52]

FAQs

1. Is CDA type I curable? Sometimes. Stem cell transplant is the main curative option for severe cases, but it is used only in carefully selected patients. [53]

2. Is interferon important? Yes. It is the best-studied disease-directed medical treatment for CDA I. [54]

3. Do all patients need transfusions? No. Severity varies widely. Some need only occasional support. [55]

4. Can iron overload happen without many transfusions? Yes. Ineffective erythropoiesis itself can increase iron loading. [56]

5. Is splenectomy a routine cure? No. It is not a standard answer for CDA I. [57]

6. What genes are involved? Most often CDAN1 or CDIN1. [58]

7. Is it inherited? Yes, usually in an autosomal recessive pattern. [59]

8. Can children be affected from birth? Yes. Some cases begin before birth or in infancy. [60]

9. Why do gallstones happen? Chronic red cell breakdown increases pigment production in bile. [61]

10. Why is ferritin checked? It helps track body iron burden. [62]

11. Are chelators safe? They can help a lot, but they need kidney, liver, blood count, and other safety monitoring. [63]

12. Do supplements cure it? No. They are supportive only. [64]

13. Can pregnancy be managed safely? Often yes, but it needs close specialist care. [65]

14. Is genetic testing useful? Yes. It helps confirm diagnosis and guide family counseling. [66]

15. What is the biggest long-term risk? Ongoing anemia plus iron overload and its organ complications are major concerns. [67]

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: April 01, 2025.

Previous

Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

Next

Congenital Dyserythropoietic Anemia, Type III

Related Articles

Added to wishlistRemoved from wishlist 0

Congenital ectropion uveae

Added to wishlistRemoved from wishlist 0

Congenital Dyserythropoietic Anemia, Type III

Added to wishlistRemoved from wishlist 0

Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

Added to wishlistRemoved from wishlist 0

Congenital Dyserythropoietic Anemia Due to KLF1 Mutation